U.S. biotech company chooses OmniComm's SaaS model for 4 clinical studies

OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that its TrialMaster® suite of applications and IVRS technology has been chosen by a prominent biotechnology company to manage their clinical data management and randomization needs for 4 key clinical trials.  All 4 studies, leveraging OmniComm's Software-as-a-Service (SaaS) rapid-deployment model, will be put into production by the end of May.

"We are honored to be chosen by this biotech firm to manage so many key studies," said Stephen Johnson, President & COO of OmniComm.  "Our past experience with this company, and the trust that we've built with them to get these studies up and running under such tight timelines, were pivotal in their selection of OmniComm.  We look forward to the challenge."

OmniComm has also recently become a Society for Clinical Data Management CCDM® partner, an achievement that is only bestowed upon companies that are committed to quality clinical data management and Certified Clinical Data Manager (CCDM) credentialing.  Qualifying companies must have at least 10 certified CCDMs or 25% of CDMs must have achieved certification.